Enovis CORP (ENOV) stock intrinsic value fair value estimate & owner earnings analysis

Enovis is a medical-technology company with two segments: Prevention & Recovery (braces and supports such as DonJoy, recovery-science devices, rehabilitation products) and Reconstructive (hip, knee, shoulder, foot-and-ankle implants, the Empower knee system and surgical-productivity tools, greatly expanded by the January 2024 purchase of Lima). Sales were $2.25 billion in 2025 and $1.17 billion in the first half of 2026 (up about 4% on the first half of 2025). The company was created by the 2022 spin-off of its industrial arm (ESAB) and the 2022 purchase of DJO, so we measure it only from 2023, the first full year as a pure medical-technology business. How we measure earnings. We start from operating cash flow, strip out swings in receivables, inventory and payables, deduct stock compensation as a real cost, and deduct the part of capital spending needed to keep the business running. On that basis owner earnings were about +$0.33 per share in 2023, about -$0.91 in 2024 (Lima closing and integration year, with $78 million of deal and integration costs) and about -$0.30 in 2025 (with $60 million of such costs). Heavy accounting losses (goodwill write-downs of $645 million in 2024 and $1.05 billion in 2025) are non-cash and are already excluded; they are, however, evidence that acquisitions have not earned their price, which shapes our downside. Capital spending is high, about 8-9% of sales, largely instruments and equipment, and nearly all of it is treated as maintenance because most sales growth has come from acquisitions. Level used. We take 2023 and 2025 as the representative years (2024 is distorted by the Lima closing) giving roughly break-even owner earnings, then credit only what has already been reported: in the first half of 2026 owner earnings improved by about $39 million versus the first half of 2025 (operating cash flow $99 million versus $46 million, with capital spending up to $97 million). Assuming the second half repeats last year, 2026 owner earnings are about $0.38 per share. Growth check: 2025 improved by about $0.61 per share over 2024; the 2026 assumption improves by about $0.68 per share, supported by the reported first-half figures. No further growth is credited: market expansion, new products, share gains and margin expansion are not yet demonstrated on a cash basis, and roughly $174 million a year of acquired-intangible amortisation signals that acquired product lines wear out. Base case, about $3.60 per share. Owner earnings hold at about $0.38 per share for ten years, then fade to zero over a further ten years as acquired brands, technology and implant designs age and reinvestment needs absorb the cash. The installed base of implants and bracing brands is why we do not assume an abrupt end. Bear case, about -$0.80 per share. Owner earnings stay near the 2025 level of -$0.30 for three years as integration and deal spending, high capital intensity and the roughly $1.3 billion of debt (a $460 million convertible and revolver due 2028, a $708 million maturity in 2030, and a lender covenant limiting secured debt to 3.75x earnings, stepping down to 3.5x) absorb all cash; afterwards we credit nothing. Two consecutive years of large goodwill write-downs support treating further acquisition losses as a named risk. On this case the business is worth slightly less than nothing to shareholders after interest costs, meaning the company appears to owe more than the cash it earns. Bull case, about $10 per share. The Lima-related integration and strategic transaction costs (about $60 million in 2025) fall away as they have begun to (from $78 million in 2024), lifting owner earnings to roughly $1.10 per share, held ten years and then faded over ten more. What would make this wrong: second-half 2026 cash flow failing to repeat last year's strong second half (2025 operating cash flow was $46 million in the first half and $171 million in the second), further acquisitions that consume cash or create new write-downs, or capital spending rising further. Conversely, sustained lower integration costs would push value toward the bull case. Our latest quarterly filing text was not available, so 2026 figures come from the reported quarterly financial data only. Margin-of-safety price: because owner earnings are thin, leverage is meaningful and acquisitions have repeatedly been written down, the margin-of-safety price is set with a large margin of safety (about 60% below the base case) and depends on evidence that the first-half cash-flow improvement carries through the full year.